Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715786 | 0.90 | CCR3 (0.62) | SLC6A5DRD4CCR3SIGMAR1CHRM2 | |
| SCHEMBL6715536 | 0.89 | SLC6A5 (0.65) | SLC6A5DRD4CCR3SIGMAR1CHRM2 | |
| Hydrochloric Acid SCHEMBL6715783 | 0.88 | SLC6A5 (0.64) | SLC6A5DRD4CCR3SIGMAR1CHRM2 | |
| SCHEMBL6715492 | 0.86 | CCR3 (0.56) | SLC6A5DRD4CCR3CHRM2CHRM1 | |
| Fumaric Acid SCHEMBL6713953 | 0.84 | SLC6A5 (0.59) | SLC6A5DRD4CCR3SIGMAR1CHRM2 | |
| SCHEMBL6714169 | 0.83 | CCR3 (0.48) | DRD4CCR3CHRM2CHRM1SSTR5 | |
| SCHEMBL6716204 | 0.81 | CCR3 (0.48) | DRD4CCR3CHRM2CHRM1SSTR5 | |
| SCHEMBL13663051 | 0.81 | EPHX2 (0.69) | SLC6A5DRD4 | |
| SCHEMBL6714325 | 0.80 | MCHR1 (0.57) | DRD4CCR3CHRM2CHRM1CHRM3 | |
| SCHEMBL6719419 | 0.80 | CCR3 (0.51) | DRD4CCR3CHRM2CHRM1SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | claimed |
| EP-1335912-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GmbH (DE) | 2003-08-20 | — | — | EP | claimed |
| WO-2002042291-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | claimed |
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1335912-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002042291-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | LIPC, CETP, MTTP | SLC6A5 811/4885DRD4 2894/4885CCR3 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.